RxDoctor Payments DataLook up a doctor →

Jeanna Knoble, MD

Hematology & Oncology · Columbus, OHNPI 1548242118

Payments from drug & device makers

$814,186in general payments, 2019–2025

Across 459 payments — averaging $1773.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$272K
  • Seagen Inc.$191K
  • Bristol Myers Squibb$107K
  • Merck$103K
  • Genentech, Inc.$69K
  • Eli Lilly$20K
  • plus $53K from 54 others
$9,386in research payments, 2019–2025

Across 5 payments — averaging $1877.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$6K
  • Eli Lilly$4K

What the payments were for

  • Consulting fees$15,39344%
  • Speaking & faculty fees$7,77822%
  • Travel & lodging$4131%
  • Food & beverage$10,25129%
  • Education$880%
  • Other$1,2804%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)50$272,463
Seagen Inc.57$191,160
Bristol Myers Squibb22$106,540
Merck6$102,686
Genentech, Inc.25$68,642
Eli Lilly9$19,689
F. Hoffmann-la Roche AG4$13,150
Pfizer18$11,726
Daiichi Sankyo Inc.12$4,831
Novartis29$3,506
Rigel Pharmaceuticals, Inc.9$3,349
Exelixis Inc.5$2,748
Incyte Corporation5$1,618
Geron Corporation2$1,560
CTI Biopharma Corp.3$1,476
Puma Biotechnology, Inc.1$1,000
Veracyte, Inc.2$994
Johnson & Johnson6$858
E.r. Squibb & Sons, L.L.C.20$776
Spectrum Pharmaceuticals Inc.1$750
Eisai Inc.25$490
Amgen8$315
Takeda Pharmaceuticals U.S.A., Inc.7$243
Pharmacyclics LLC, An Abbvie Company6$228
Heron Therapeutics, Inc.2$228
AVEO Pharmaceuticals, Inc.8$182
Dova Pharmaceuticals6$166
EMD Serono, Inc.10$151
Mirati Therapeutics, Inc.2$145
Sirtex Medical Inc1$142
Sanofi7$135
Flowonix Medical Incorporated1$134
Janssen Scientific Affairs, LLC1$131
Regeneron1$129
Bayer1$129
Taiho Oncology, Inc.8$114
Array Biopharma Inc4$109
Gilead(2 entities)6$102
Genentech USA, Inc.5$101
AbbVie3$87
GSK4$83
Jazz Pharmaceuticals Inc.3$81
Astellas Pharma US Inc4$77
Ipsen Biopharmaceuticals, Inc4$76
Pharmacosmos Therapeutics Inc.4$71
Karyopharm Therapeutics Inc.4$65
Agios Pharmaceuticals, Inc.2$64
Servier Pharmaceuticals LLC3$64
Lilly USA, LLC3$58
Regeneron Healthcare Solutions, Inc.2$52
Springworks Therapeutics, Inc.2$48
Coherus Oncology, Inc.3$46
ADC Therapeutics America, Inc.3$43
Tersera Therapeutics LLC1$40
AMAG Pharmaceuticals, Inc.2$35
Acceleron Pharma, Inc.2$33
Iovance Biotherapeutics, Inc.2$31
Foundation Medicine, Inc.2$27
Octapharma USA, Inc.1$25
Sun Pharmaceutical Industries Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$814,186 in reported general payments places this provider in the 85th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$1,270,003
Medicare patients
313
Services billed
46,794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib55$857,387
RevlimidLenalidomide24$422,504
BrukinsaZanubrutinib29$396,305
ImbruvicaIbrutinib21$312,432
XareltoRivaroxaban19$12,782
Letrozole436$9,071
Fondaparinux Sodium11$9,036
Exemestane19$5,109
Tamoxifen Citrate128$5,092
Hydroxyurea46$1,099
Oxycodone Hcl28$1,045
Anastrozole67$1,032
Dexamethasone12$411
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$298
Ondansetron Hcl21$212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance$11,726$857,38755 claims
Bristol Myers SquibbRevlimid$106,540$422,50424 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$228$312,43221 claims
Johnson & JohnsonXarelto$858$12,78219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →